– USA, MA – Mediar Therapeutics today announced the appointment of Simon Sturge to its Board of Directors as Executive Chairman, bringing extensive experience in both large pharmaceutical operations and biopharma startups to Mediar as it advances a novel platform technology focused on the myofibroblast, a cell that is a key driver in fibrosis pathology.
“We are thrilled to welcome Simon to Mediar as we move towards bringing our breakthrough treatments for fibrosis to the clinic,” said founding CEO, Dr. Meredith Fisher. “Simon’s impressive record driving drug development and leading major biopharma organizations makes him the perfect team member to lead Mediar through its next stage of development.”
About Simon Sturge
Most recently, Simon Sturge served as CEO of Kymab, a company developing innovative antibody treatments. He spearheaded the company’s sale to Sanofi S.A. earlier this year for up to $1.45 billion. Prior to joining Kymab, Sturge was COO of Merck Healthcare, responsible for the company’s global commercial and manufacturing operations, as well as serving as a member of Merck’s healthcare executive board.
Earlier, Sturge was SVP, biologicals at Boehringer Ingelheim where he ran the German biopharma’s global biosimilars business. He also served as chairman at two biopharma startups, Silence Therapeutics and Nemesis Biosciences.
“I’m excited to help lead Mediar into its next stage of development. I believe my background developing and advancing novel antibody-based therapeutics at Kymab will be especially helpful as Mediar builds a pipeline of antibody-based treatments for fibrosis,” said Simon Sturge.
He added, “Mediar’s plan to target fibrotic mediators to halt, and even reverse, fibrosis has the potential to transform the way we treat this disease, which manifests in many different forms throughout the body.”
About Mediar Therapeutics
Mediar Therapeutics is a discovery stage biotechnology company developing treatments to halt, or even reverse, fibrosis. Our platform and pipeline are based on an emerging class of novel targets – fibrotic mediators – that play key roles in modulating myofibroblasts. These cells are drivers of pathophysiology in diseases such as liver cirrhosis, which can leave organs chronically damaged. Mediar was co-founded by leading fibrosis researchers from Massachusetts General Hospital and Brigham and Women’s Hospital in 2019.
Earlier this year, Mediar announced that Pfizer Ventures and Ono Venture Investment had invested in the firm, bringing the total seed round to $20 million.
For more information : https://www.mediartx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.